Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (4067)	6/7/2001 9:29:59 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

The relative capitalizations....... They're buried in history. There was Cell Genesis, and there was GenPharm. Cell Genesis sued GenPharm. GenPharm won, but had to all-but-close-their-doors in the course of the fight. The settlement led to a cross-license. Cell Genesis spun out ABGX, free of baggage. Medarex, loaded with crap (baggage), bought GenPharm's unit that was devoted to "the mouse". As a result, footloose ABGX attracted a variety of suitors (partners). MEDX, otoh, was looked at with a jaundiced eye while trying to integrate and develop the GenPharm technology. ABGX therefore got off to a quicker start. They also seemed to make the first improvements to "the mouse". MEDX's management is also regarded, IMO, as slightly more prone to exaggeration.